About
Independent information on Mounjaro (tirzepatide)
What is Mounjaro Info?
Mounjaro Info is an independent information website dedicated to Mounjaro (tirzepatide), a medication developed by Eli Lilly. Our mission: making medical and scientific information about tirzepatide accessible in French, English and Traditional Chinese.
Tirzepatide at a glance
Tirzepatide is a dual GIP and GLP-1 receptor agonist, a new class of medication that acts on two hormonal pathways to:
- Improve glycemic control in type 2 diabetes patients
- Promote significant weight loss
- Reduce cardiovascular risk factors
Regulatory approvals
- FDA (United States): approved May 2022 for type 2 diabetes
- EMA (Europe): approved September 2023
- Zepbound: weight management formulation (FDA, November 2023)
Our approach
Every day, we collect the latest news, clinical studies and developments related to tirzepatide. This information is:
- Verified from medical and scientific sources
- Reformulated by artificial intelligence for clarity
- Published in three languages
Disclaimer
The information published on this site is for informational purposes only. It does not constitute medical advice, a treatment recommendation, or an encouragement to self-medicate. Always consult a healthcare professional before starting or modifying any treatment.